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ABSTRACT  
Background: Bacterial skin and soft tissue infections (SSTIs) are a health issue for people who inject 
drugs (PWID).   There is a lack of evidence on the associations between harm reduction (HR) uptake 
and SSTIs. This paper examines the associations between the uptake of injecting equipment (IE) and 
opiate substitution treatment (OST) on SSTIs among PWID, and the injecting behaviours associated 
with having had a SSTI. This is the first large-scale, national study to examine the association 
between IE uptake and SSTIs. 
Methods:  A cross-sectional, voluntary and anonymous survey was undertaken with PWID recruited 
from pharmacies/agencies providing IE across mainland Scotland during 2013-2014.  Participants 
were asked: if they had a SSTI within the past year; about their uptake of HR within the past 6 
months (including needle/syringes (N/S), paraphernalia and OST); and about their frequency of 
injecting, sharing of IE and re-use of own N/S. Data from 1876 PWID who had reported injecting 
within the past 6 months were analysed. 
Findings: In multivariate logistic regression, those with high combined IE-OST uptake (adjusted odds 
ratio [AOR] 0.614, 95% CI 0.458-0.823, p = 0.001) and medium combined IE-OST uptake (AOR 0.725, 
95% CI 0.546–0.962, p = 0.026) had lower odds of having had a SSTI compared to those with low 
combined IE-OST uptake.   
Conclusions: IE and OST uptake may reduce the level of SSTIs among PWID, suggesting increasing 
combined uptake maybe beneficial. Nevertheless, a sizeable proportion of PWID with high HR 
uptake experienced SSTIs, suggesting the importance of other interventions. 
Keywords: people who inject drugs; skin and soft tissue infection; bacterial infection; injecting 
equipment; opiate substitution treatment; harm reduction 
 
  
Page 3 of 15 
 
 
 
1. Introduction  
Bacterial skin and soft tissue infections (SSTIs) are a health issue for people who inject drugs (PWID).   
Infections are caused by a number of bacteria, such as those from the injectors’ own skin, and those 
present in contaminated drugs, cutting agents or injecting paraphernalia (Gordon and Lowy, 2005). 
Although most of these infections are localised, mild and superficial, they can result in serious 
morbidity and mortality when associated with systemic symptoms such as fever, rapid heartbeat or 
low blood pressure,  or with  a co-morbidity, sepsis syndrome or a life-threatening infection, such as 
necrotizing fasciitis (Dryden, 2009). Harm reduction (HR), such as the provision of sterile injecting 
equipment (IE) or opiate substitution treatment (OST), may be important to help prevent the 
potential onset of serious infection (Hope, 2010).  
Commonest forms of injection site SSTIs are abscesses or cellulitis (Fink et al., 2011; Hope, 2010). 
Prevalence studies from Europe, North America and Australia have shown that 21% to 32% of PWID 
had a current abscess (Binswanger et al., 2000; Morrison et al., 1997; Saeland et al., 2014); 7% to 
36% had an abscess or open wound within the past year (Dwyer et al., 2009; Hope et al., 2010; 
Maloney, 2010; Phillips and Stein, 2010; Public Health England et al., 2014). Re-use or sharing of 
unsterile needles and syringes (N/S) has been shown to be associated with increased SSTI prevalence 
(Hope et al., 2014b; Hope et al., 2008; Lloyd-Smith et al., 2008; Maloney, 2010), as has the re-use 
and sharing of injecting paraphernalia, in particular, filters and flush water (Hope et al., 2010). More 
frequent injecting is also associated with SSTIs (Hope et al., 2014b; Hope et al., 2010; Phillips and 
Stein, 2010): repeated injections damage the skin and tissues providing a focus for infection (Pieper 
and Hopper, 2005). Limited research exists examining the association between HR, such as IE 
provision and OST, and SSTIs among PWID. The total number of clean N/S distributed from a needle 
exchange (NE) and the opening of a NE were shown to be associated with reduced SSTI prevalence 
(Bhattacharya et al., 2006; Hart et al., 1989; Tomolillo et al., 2007). None of these small scale single 
site studies showed the level of injection equipment (IE) uptake needed per individual for use sterile 
IE for every injection. Those who took OST in the past but not currently had higher odds of having 
had a SSTI in the past year (Hope et al., 2008). Others have demonstrated that combined high 
uptake of N/S and  OST was associated with reduced incidence of HCV among PWIDs in Scotland 
(Palmateer et al., 2014); and OST and IE provision services have been shown to reduce self-reported 
injecting risk behaviours, such as the borrowing, lending, re-use of N/S or paraphernalia, and 
injecting frequency (MacArthur et al., 2014); and IE provision (IEP) and OST are associated with 
reduced HIV infection (Degenhardt et al., 2010; Palmateer et al., 2010). Notably, no study has 
examined the associations between the uptake of sterile IE, or the combined effect of IE and OST 
uptake, on SSTIs. This paper will be unique by analysing data from a national survey of PWID 
conducted in Scotland.  The paper also examines injecting behaviours associated with having had a 
SSTI. 
 
2. Materials and methods  
2.1 Data source 
Data used for this paper was gathered in 2013-2014 as part of the Needle Exchange Surveillance 
Initiative (NESI) Scotland study. NESI is a cross sectional, voluntary, and anonymous survey, which 
has been on-going since 2008 (University of the West of Scotland et al., 2015). Between February 
2013 and February 2014, participants were recruited from 106 pharmacies and 28 agencies 
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providing a fixed site, mobile or outreach IEP service across Scotland’s eleven mainland NHS Health 
Boards. Healthcare for Scotland is devolved to regional Health Boards. Trained interviewers asked 
eligible participants to participate in a 15 minute face-to-face questionnaire. Those eligible had 
injected drugs at least once in the past and had not already participated in the current data 
collection sweep. The questionnaire included questions on drug use history, injecting risk behaviours 
and harms, IE and OST uptake and participant demographics. All participants provided informed 
consent, were provided with a £5 shopping-voucher and interviews were conducted in a private 
room.  Ethics approval was obtained from the West of Scotland NHS Research Ethics Committee.   
2.2 Measures  
 
2.2.1 Outcome measure 
This was measured using the question ‘In the last year, have you had a swelling containing pus 
(abscess), a sore or open wound at an injection site?’   
2.2.2 Intervention measures 
HR interventions considered were IE uptake and OST, that is, methadone. These measures which 
were derived from the questionnaire have been used in previous work (Palmateer et al., 2014) and 
included uptake of: i) N/S, ii) paraphernalia, iii) combined IE (N/S and paraphernalia) , iv) OST, and v) 
combined IE  and OST. 
N/S uptake was derived by dividing the self-reported number of N/S obtained in the last six months 
by the self-reported number of injections in the last six months. This was categorised into high and 
low uptake. The threshold for high uptake (200%+, at least twice as many N/S as injections) has been 
used in previous work, where it was chosen on the basis of sensitivity analyses (Palmateer et al., 
2014). Paraphernalia uptake was derived by combining filter and spoon uptake. Those who reported 
high uptake (200%+) of both spoons and filters were classified as having high paraphernalia uptake, 
with the remaining falling into low category. A combined variable, called IE uptake, was derived 
where those with high uptake (200%+) on both N/S and paraphernalia were categorised as high and 
the remaining were categorised as low. OST uptake was defined as ‘never been on OST’, ‘currently 
on OST at the time of the study’ or ‘on OST in the past but not currently’.  A final combined uptake 
variable was derived by combining IE and OST uptake, with categories low, medium and high.  In 
order to derive this combined variable, those who had ‘never been on OST’ or ‘on OST in the past 
but not currently’ were combined to represent not currently on OST.  The ‘Low combined IE-OST’ 
uptake category included those with low IE uptake and were not currently on OST; ‘medium 
combined IE-OST’ uptake included those with either low IE uptake and were currently on OST, or had 
high IE uptake but were not currently on OST; ‘high combined IE-OST’ uptake included those who 
had high IE uptake and were currently on OST.  
2.2.3 Injecting behaviours 
Injecting behaviours included frequency of injecting, sharing IE and re-use of one’s own N/S. These 
were self-reported and related to the past 6 months. Frequency of injection was categorised as daily 
or more, or less than daily. Sharing IE (including N/S, spoons and filters) was categorised as yes/no. 
Re-using one’s own N/S was measured as yes/no to record if the N/S had been re-used more than 
once.  
 
2.3 Statistical Analysis 
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Logistic regression was used to calculate the odds of self-reported SSTI associated with i) uptake of 
the HR interventions and ii) injecting behaviours. Associations between other variables and SSTI 
were also explored using Pearson’s χ2test (Table 1).  The confounders selected for inclusion in the 
multivariate logistic regression were those found to be statistically significant (p<0.05) using the 
bivariate analysis in Table 1 and those previously found to be associated with SSTI prevalence.  The 
potential confounders included Health Board area, time since onset of injecting, injection of more 
than one drug (‘poly-drug use’), gender and homeless in the past six months. Poly-drug use was 
included, rather than stimulant use, to incorporate the number of emerging new psychoactive 
substances (NPS) injectors in the sample – such as ‘Burst’. For time since onset of injecting, ‘<5 
years’ and ‘5-10 years’ was collapsed to ‘<10 years’ to give a reference group with a larger sample 
size. Injecting risk behaviour and injecting frequency variables were not considered for the 
regression models examining HR interventions and SSTI because they are on the causal pathway, but 
injecting frequency was included as a confounder in the regression model for SSTI and sharing IE, 
and re-use of N/S. Multivariate regression was generated by forward step-wise analysis and was 
statistically significant at p<0.05 (Table 2 and Table 3). Analyses were undertaken with SPSS version 
22. 
 
3. Results 
Of the 2463 participants, 119 duplicate records from individuals who had participated more than 
once were excluded. Of the remaining 2344 respondents, those who had not injected within the past 
6 months (n=402), those who exclusively injected bodybuilding drugs (n=58), as this group were less 
likely to have had a SSTI, and those with missing injecting status (n=9) were excluded.  The remaining 
1876 participants were analysed. 
Of the sample, 28% (533/1876) had reported a SSTI in the past year, 30% (555/1866) were female, 
52% (984/1875) were aged 35 years or more and 38% (714/1874) had been injecting for less than 10 
years. The majority were currently prescribed methadone (71%, 1326/1875), 78% (1472/1874) had 
injected heroin only in the past six months and 37% (530/1436) had been homeless in the past six 
months, and 66% (1240/1865) were ever in-prisoned. Table 1 shows that those who had a SSTI 
within the past year were more likely to be from an East of Scotland Health Board area, injected for 
20 years or more, or were poly-drug injectors. 
 [TABLE 1 IN HERE] 
 
Table 2 presents the associations between the uptake of HR interventions in the previous 6 months 
and having had a SSTI within the past year. The multivariable analysis was controlled for Health 
Board area, years of injecting, poly-drug use, gender and homeless in the past six months. 
Multivariable analysis demonstrates that those with high N/S (Model 1), high paraphernalia (Model 
2), high IE (Model 3) uptake all had lower odds of having had a SSTI relative to those with low 
uptake.  N/S and paraphernalia uptake was highly correlated (CRAMERS V = 0.79, p=0.000).  Those 
individuals who had never been on OST or were currently on OST had lower odds of having had a 
SSTI than those previously on OST (Model 4). Further analysis shows that those who had never been 
on OST were more likely to be the early-stage injectors - 72% (117/162) of those who had never 
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been on OST had been injecting for less than 10 years compared to 35% (467/1325) of those 
currently on OST and 33% (129/386) of past users of OST (χ2=91.04, p=0.000, n=1853), and they 
were on average 3 years younger (mean = 33.61, sd = 9.39) (F(2, 1871) = 15.59, p=0.00). However, a 
sizeable number of those never on OST injected daily (57%, 92/162).  
Model 5 examines the combined IE-OST uptake. Those individuals with the highest or complete level 
of uptake (high IE uptake and currently on OST), and those with medium uptake (either low IE and 
on OST, or high IE and no OST) had lower odds of having had a SSTI compared to those with low 
uptake (low IE uptake and no OST).  Across all five models, those with high combined uptake had 
marginally the lowest odds of having had a SSTI.  
Table 3 shows that those who injected daily or more, shared any IE or re-used N/S had higher odds 
of having had a SSTI in the past year.  Notably, 21% of those who did not inject daily or more, or re-
use N/S and 25% who did not share any IE still experienced a SSTI.  
 
[TABLE 2 IN HERE] 
 
[TABLE 3 IN HERE] 
 
4. Discussion  
Our study shows that 28% of PWID had a self-reported SSTI within the past year and those PWID 
with high combined IE-OST uptake or medium combined IE-OST uptake had lower odds of having 
had a SSTI compared to those with low combined IE-OST uptake.  Nevertheless, 24% of PWID with 
high HR uptake still experienced a SSTI within the past year. 
Our prevalence of 28% is within the range of prevalence reported internationally where 7% to 36% 
of PWID had an abscess or open wound within the past year (Dwyer et al., 2009; Hope et al., 2010; 
Maloney, 2010; Phillips and Stein, 2010). However, it is difficult to make direct comparisons with 
other studies due to the heterogeneity of PWID definitions, recruitment strategies and sampling. 
Little is known about the impact of HR interventions on SSTIs. During the late 1980s NE services were 
piloted in Scotland (Stimson et al., 1988) however a need to action an expansion and improvement 
of IEP services across all NHS Boards and the development of guidelines was identified as part of a 
national Hepatitis C Action Plan (Phase II: 2008-2011) (The Scottish Government, 2008, 2010).  
Scotland now has a comprehensive HR programme which provides unlimited free access to IE 
(including N/S, spoons, filters, acidifiers, water for injection and pre-injection swabs) as advocated in 
national IEP guidelines, and OST, mainly via pharmacies and drug treatment agencies (The Scottish 
Government, 2010).  The IEP guidelines focused on the prevention of HCV but they recognised that 
provision of sterile IE alongside safer injecting advice (washing hands with soap and water before 
injecting, and the correct IE usage) may also impact on SSTIs.   
Our findings suggest that Scotland’s HR provision of IE and OST impacts on SSTIs but it is noteworthy 
that a sizeable proportion of PWID with high HR uptake still experienced SSTIs. High IE uptake 
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relative to low IE uptake within the past six months was associated with lower odds of having had a 
SSTI within the past year, as was being currently on OST relative to having been on OST in the past. 
Approximately a third of PWID with low IE or OST uptake had a SSTI within the past year, compared 
to approximately a quarter of PWID with high IE or OST uptake. Notably, the combined effect of high 
IE and-OST had marginally the lowest odds of having had a SSTI. Consequently, increasing the 
provision of clean IE coupled with OST may be a beneficial HR intervention for SSTIs. The mismatch 
in timeframes for IE uptake (six months) and presence/absence of a SSTI (one year) occurred 
because of the nature of the data available; SSTI over a one year period was collected to allow 
comparability with other prevalence studies. This mismatch may tend to under-estimate the 
association being measured, and therefore our finding is conservative. 
Further analysis showed that those who shared any IE, re-used N/S or injected daily or more had 
higher odds of having had a SSTI in the past year. Others have also shown that sharing or re-using 
N/S is associated with increased SSTI prevalence (Hope et al., 2014a; Hope et al., 2008; Lloyd-Smith 
et al., 2008; Murphy et al., 2001), as is the re-use and sharing of injecting paraphernalia (Hope et al., 
2010). Earlier work using previous sweeps of NESI has established that high IE uptake and being on 
OST reduced the odds of sharing N/S, spoons or filters, and of injecting daily or more respectively 
(Palmateer et al., 2014).  
The uptake of at least twice as much IE as needed, that is high uptake (200%+), may be protective 
against SSTIs. Firstly, injectors may have difficulty accessing veins (Hope et al., 2016) and may need 
several needles to achieve one successful injection. Secondly, plentiful supplies cover times of poor 
access to IEP services, for example, Sundays or evenings. An ample supply of sterile IE may negate 
the need to share or re-use needles that may have become contaminated with bacteria. Bacterial 
contamination of injecting equipment such as syringes, cookers (Tuazon et al., 1974) and filters 
(Caflisch et al., 1999; Scott, 2008) has been observed.  Equally, it cannot be discounted that 
participants may have over-estimated their IE uptake.   
Interestingly, the odds of having had a SSTI were higher among those who were previously (but not 
currently) on OST; this is consistent with Hope et al.’s (2008) findings, and mirrors the pattern of 
association between OST and HCV infection (Allen et al., 2012). The nature of this association is 
unclear and further research is needed.  It may be suggestive of a number of factors including: those 
no longer on OST were those who have failed in treatment, for whatever reason, and have relapsed 
into injecting representing a high-risk group by possibly engaging in risker practices which 
contributed to a higher SSTI occurrence (e.g. more frequent injecting, experiencing more missed 
hits, less cleaning of injections sites) or there is less contact with HR information/advice from drug 
treatment services or the factors that explain why they were no longer engaging with OST also 
explain the higher SSTI occurrence.  Also, those PWID who had never been on OST had the lowest 
odds of having had a SSTI – these individuals were perhaps those with less tissue damage because of 
shorter injecting careers or non-progression to groin injecting. However, a sizeable proportion of 
those who were never on OST were frequent injectors and it may be that, in time, this group will 
experience more SSTIs if interventions or safer injecting practices are not taken up. 
Due to the cross-sectional nature of the data collection, we cannot infer causality and need to be 
mindful of alternative explanations for the associations between IE/OST uptake and SSTIs – that is, 
high IE uptake, per se, may not be the main reason for the lower SSTI prevalence but may be a 
marker for other factors associated with the outcome.  For example, it is possible that those who 
have high IE uptake were a low-risk group who engaged in other safer practices (such as hand 
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washing, injection site cleaning or injecting site rotation not included in the model) that reduced SSTI 
risk.  Similarly, high IE uptake may reflect PWID who use HR services more frequently and are thus 
more likely to receive education/support about injecting practice and hygiene.   
Equally, there are many potential causes of SSTI among PWID other than sharing/re-use of IE, 
including environmental contamination from public injecting, groin or hand injecting, poor personal 
hygiene, contaminated drugs, damaged skin/tissue due to missed hits or overuse of citric 
acid/Vitamin C. These other causes may explain why a quarter of PWIDs had experienced a SSTI 
within the past year despite high HR uptake.  Additionally, approximately a fifth of those who did not 
inject daily or had not re-used their N/S had a SSTI and a quarter of those who had not shared any 
piece of IE had a SSTI. In other words, IEP and OST cannot mitigate against all risks of bacterial 
infection and other forms of HR are equally, if not more, important such as: promoting and 
facilitating hand washing, swabbing injection sites, injection site rotation, preventing transition to 
injecting, vein and wound care and advising PWID to seek timely healthcare during, for example, 
outbreaks of serious infections arising from spore-forming bacteria.  However, the effectiveness of 
behavioural change interventions can be undermined by situational and social contexts of injecting 
(Moore, 2004). Being in a hurry or impatient to inject, being in withdrawal plus not having clean 
supplies and not thinking about skin cleaning are barriers to self-initiated skin cleaning (Bonar and 
Rosenberg, 2014) ; also PWID keep used filters to extract residual drugs (Taylor A. et al., 2004) and 
these filters may harbour bacteria (Scott, 2008).  Consequently, notwithstanding the high uptake of 
HR, health services will be needed to respond to SSTIs (Hope, 2010).  
IEP services may provide more effective HR for SSTIs if combined with other services such as drug 
consumption rooms (DCRs) or nurse-led wound clinics (Bassetti and Battegay, 2004; Hope, 2010).  
Care for SSTIs can be delivered via specialised clinics set up in DCRs (Fast et al., 2008; Lloyd-Smith et 
al., 2010), hospitals (Harris and Young, 2002), IEP sites (Grau et al., 2002; Nesbitt, 2015) including 
mobile outreach IEP services (Robinowitz et al., 2014) and via charitable organisations (Finnie and 
Nicolson, 2002).  Guidelines advocate that specialist IEP programmes should offer comprehensive HR 
packages including advice on safer injecting practices, assessment of injection site infections and 
SSTI treatment/referral (NICE, 2014).   
Non-intervention variables found to be associated with increased odds of having had a SSTI included: 
residing in an East of Scotland Health Board area, longer injecting histories and poly-drug use. 
Further work is needed to explain the regional differences – these may in part reflect regional 
differences in the drugs taken – for example, SSTI problems are emerging among NPS injectors, 
specifically Lothian in the  East of Scotland which has experienced an increase in injecting of 
ethylphenidate (Lafferty et al., 2016) or contamination of local drug supplies.  Analysis (not shown) 
stratifying injecting history as “< five years” versus “≥ five years” was not statistically significant 
suggesting that within our sample, it is those with longer injecting histories (such as 20 years plus) 
rather than new injectors that were experiencing more SSTIs. Interventions targeted to the above 
groups may help reduce SSTI harms. The similar SSTI prevalence between those “ever been in 
prison” and “never in prison” may be explained by the low levels of in-prison injecting within 
Scottish prisons because of the range of HR policies, particularly the increased OST availability 
(Taylor et al., 2013).  This suggests that most SSTIs were acquired within the community rather than 
in-prison. 
 
4.1 Limitations 
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There are a number of limitations. Firstly, it cannot be discounted that selection bias occurred. The 
survey sampled PWID who are in contact with IEP services, which may result in an under-estimation 
of SSTI prevalence among high-risk injectors not in contact with such services.  On the other hand, if 
these IEP services offered wound care clinics there may have been an over-representation of PWID 
with SSTI who were seeking advice/treatment. Secondly, we were unable to ask questions about 
other HR practices pertinent to SSTIs, such as hand washing, swabbing, injecting site rotation or 
other risk factors such as skin/muscle popping, quantity of citric acid used, filter re-use, needle 
licking or healthcare seeking behaviours for SSTIs. Thirdly, the uptake of IE was measured over a six 
month timeframe whilst the prevalence of SSTIs was measured over the past year. This occurred 
because of the nature of the data available, and may have lessened the association between the 
outcome and exposure variables. Fourthly, the presence/absence of a SSTI was determined by self-
report. We cannot discount that for some participants a SSTI may have been forgotten, not deemed 
worthy of mention or another skin problem was reported as a SSTI.  However, Morrison et al (1997) 
found that PWID self-report of current injecting related harm, including abscesses, conferred with 
medical examination, and suggests accurate self-reporting. 
 
4.2 Conclusions and future research 
Even though high IE-OST uptake was associated with the lowest odds ratio for having had a SSTI in 
the past year, a sizeable proportion of PWID with high IE-OST uptake still experienced SSTIs.  This 
suggests that IE and OST are needed as part of a wider HR package for SSTIs.  HR services which 
provide wound/SSTI clinics delivered via DCRs or NE maybe needed.  In addition, an understanding 
of SSTIs and HR in relation to PWID lives and injecting experiences is needed to inform the 
development of services to reduce, and support PWID with, SSTIs.  
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Table 1. Demographics of PWID1 who had a SSTI2 in the past year 
Demographic N Had a SSTI 
2
 
     n  %     
P-value 
3
 
Male 
Female 
1306 
553 
374 (29)  
156 (28) 
0.852 
Ever homeless 
  No 
  Yes 
 
430 
1435 
 
118 (27) 
414 (29) 
 
0.570 
Homeless in past 6 months  
  No 
  Yes 
 
1333 
529 
 
388 (29)       
143 (27) 
 
0.371 
Ever in prison                           
  No  
  Yes 
 
622 
1238 
 
175 (28) 
356 (29) 
 
0.780 
Age (years) 
  <= 25  
  26-30 
  31-35 
  >35 
 
149 
277 
462 
980 
 
  40 (27)               
  75 (27)           
116 (25)         
302 (31)         
0.129 
Excessive alcohol 
4                        
  
  No 
  Yes 
 
1388 
475 
 
385 (28) 
145 (30) 
 
0.245 
Health Board Areas 
5
 
  West & Central  
  East  
  North 
 
1109 
540 
220 
 
290 (26) 
188 (35) 
  55 (25) 
 
0.001 
Time since onset injecting (yrs.) 
  < 10 
  10-14 
  15-19 
  20+ 
 
711 
465 
327 
364 
 
208 (29)         
118 (25)         
  79  (24)         
128 (35)         
 
0.004 
Poly-drug injection
6          
             
  No 
  Yes 
 
1567 
300 
 
399 (26) 
133 (44)  
 
0.000 
1. Defined as those who injected in past 6 months and excludes those who solely injected bodybuilding drugs 
2. Defined as self-reported swelling containing pus (abscess), a sore or an open wound at an injection site. 
3. Pearson chi square test 
4. Defined as > 14units/week for women and >21units per week for men 
5. West & Central:  Greater Glasgow & Clyde, Lanarkshire, Ayrshire & Annan, Dumfries & Galloway, Forth Valley 
East: Lothian, Fife, Tayside, Borders 
North: Highlands and Grampian 
6. Defined as use of more than one drug type in past 6 months (where drug type is Opiate, Stimulant or Other including 
Legal Highs) 
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Table 2. Univariable and multivariable models of associations between uptake of HR and SSTIs within the past year among current injectors 
Model Intervention Had a SSTI 
____________ 
n/N           (%)  
Univariable 
__________________________
OR             (95% CI)         P-value 
Multivariable 1 
___________________________ 
AOR         (95% CI)          P-value 
1 N/S Uptake 2, 3 
  Low (<200% uptake) 
  High (≥ 200% uptake) 
 
258/767   (34) 
270/1085 (25) 
 
1 
0.654 (0.533-0.801)    0.000  
 
1 
0.719 (0.581-0.888)     0.002 
2 Paraphernalia  Uptake 4 
  Low (<200% uptake) 
  High (≥ 200% uptake) 
 
258/792   (33) 
270/1060 (25) 
 
1 
0.707 (0.577-0.867) 0.001  
 
1 
0.771 (0.625-0.950)     0.015  
4 IE Uptake 5  
  Low (<200% uptake) 
  High (≥ 200% uptake) 
 
280/869   (32) 
246/979   (25) 
 
1 
0.706 (0.576-0.865)    0.001  
 
1 
0.775 (0.628-0.956)     0.017  
3 OST                                                        
  Past 
  Never  
  Current 
139/380   (36) 
  42/162   (26) 
352/1320 (27) 
 
1 
0.622 (0.413-0.936)    0.023  
0.646 (0.508-0.822)    0.000  
 
1 
0.593 (0.386-0.910) 0.017 
0.672 (0.524-0.862) 0.002 
5 Combined IE & OST 6                                      
  Low  
  Medium 
  High 
 
117/316   (37) 
225/777   ( 28) 
184/754   (24) 
 
1 
0.693 (0.526-0.914)    0.022  
0.549 (0.414-0.728)    0.000 
 
1 
0.732 (0.551-0.973)    0.032  
0.622 (0.463-0.834)    0.002 
1. All multivariable models adjusted for Poly-drug use (No, Yes), Time since onset of injecting(<10, 10-14, 15-19, 20+ year), Region (West & Central Scotland, East Scotland, North), Gender 
(Male, Female), Homeless past 6 months (No, Yes) 
2. Includes new, unused NS obtained from others 
3. Adjusts for number of months injected 
4. Paraphernalia includes spoons and filters 
5. IE includes N/S and paraphernalia.  
6. Low = Low IE, no OST; Medium = Low IE + OST, or High IE + no OST; High = High IE + OST (where No OST = never and in the past; OST = currently prescribed)  
OR= Odds Ratio, AOR= Adjusted odds Ratio, CI = Confidence Interval, N/S = needle/syringe, IE = injecting equipment, OST = opiate substitution treatment 
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Table 3. Univariable and multivariable models of association between frequency of injecting, sharing any IE, re-using N/S and SSTIs among current injectors 
Model Injecting behaviour Had a SSTI  
n/N (%) 
Univariable 
_______________________ 
OR             (95% CI)      P-value 
Multivariable 1, 2  
_________________________ 
AOR         (95% CI)          P-value 
1  Injecting frequency 
1 to 3 times a month 
About once a week 
2 to 6 times a week 
Once a day 
2 to 3 times a day 
4 or more times a day 
 
  95/511    (19) 
  35/158    (22) 
  80/327    (25) 
  64/240    (27) 
185/455    (41) 
  72/175    (41) 
 
1 
1.246 (0.805-1.928)    0.323 
1.418 (1.013-1.986)    0.042 
1.592 (1.108-2.288)    0.012 
3.000 (2.243-4.014)    0.000 
3.061 (2.105-4.452)    0.000 
 
1 
1.242 (0.798-1.932) 0.337 
1.267 (0.897-1.789) 0.179 
1.490 (1.029-2.158) 0.035 
2.703 (2.003-3.648) 0.000 
2.641 (1.791-3.892) 0.000 
2 Shared any IE in the 
last 6 months    
  No 
  Yes 
 
 
348/1363 (25) 
173/465    (37) 
 
 
1 
1.728   (1.381-2.162)   0.000 
 
 
1 
1.479 (1.164-1.878) 0.000  
3 Re-used own N/S in 
the last 6 months3    
  No  
  Yes 
 
 
188/875   (21) 
345/992   (35) 
 
 
1 
1.949   (1.583-2.398)   0.000 
 
 
1 
1.506 (1.199-1.893) 0.000 
1. Model 1 adjusted for Poly-drug use (No, Yes), Health Board Area (West & Central, East,  North), Time since onset of injecting(<10, 10-14, 15-19, 20+ years), Gender (Male, Female), 
Homeless past 6 months (No, Yes) 
2. Model 2 & 3 adjusted for Injecting Frequency (1 to 3 times a month, About once a week, 2 to 6 times a week, Once a day, 2 to 3 times a day, 4 or more times a day), Poly-drug use (No, 
Yes), Health Board Area (West & Central, East,  North), Time since onset of injecting(<10, 10-14, 15-19, 20+ years), Gender (Male, Female), Homeless past 6 months (No, Yes) 
3. Defined as re-used own N/S more than once before discarding it   
OR= Odds Ratio, AOR= Adjusted odds Ratio, CI = Confidence Interval, N/S = needle/syringe, IE = injecting equipment, OST = opiate substitution treatment 
 
 
